Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
| Status: | Recruiting |
|---|---|
| Conditions: | Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/1/2018 |
| Start Date: | May 23, 2018 |
| End Date: | January 15, 2019 |
| Contact: | Chaim M Brickman, MD |
| Email: | cbrick77@yahoo.com |
| Phone: | +972546855134 |
Phase 2B Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
This is a Phase 2 clinical study in patients with actinic keratosis involving daily
application of 1 of 2 strengths of VDA-1102 topical ointment for approximately 12 weeks (84
days). This study has no placebo and the subjects enrolled in the study will know exactly
what they are receiving. The objectives of the study are to evaluate the safety and benefit
of these two strengths.
application of 1 of 2 strengths of VDA-1102 topical ointment for approximately 12 weeks (84
days). This study has no placebo and the subjects enrolled in the study will know exactly
what they are receiving. The objectives of the study are to evaluate the safety and benefit
of these two strengths.
Inclusion Criteria:
- 4-8 grade 1 or grade 2 AK lesions in Treatment Field on face or scalp
Exclusion Criteria:
- Subject has no clinically significant findings at Baseline
- Subject is unable to demonstrate adequate precision applying the study drug to the
Treatment Field at Baseline
- Subject has in the opinion of the Investigator (a) an unstable medical, psychiatric,
social problem
- Subject has at any time been given a diagnosis or treatment associated with
immunosuppression
- Subject has received VDA-1102 in the past
We found this trial at
1
site
San Diego, California 92123
Principal Investigator: Neal Bhatia, MD
Phone: 858-571-6800
Click here to add this to my saved trials
